FDA Rules On INDs May Embolden More Patients To Ask For Trial Drugs

Pharma firms will see few policy changes following the publication of FDA's final regulations on expanded access to investigational medicine, but the revisions could nevertheless mean more patients and doctors will come knocking on their doors asking for experimental drugs